21 / 32
Direct comparisons in the STAMPEDE trial demonstrated
that PFS and FFS were significantly improved with
AA+P+ADT vs D+ADT in patients with mHSPC*
OS
PFS
§
No significant difference
in the risk of death vs D+ADT
(HR: 1.13; 95% CI: 0.77, 1.66; p=0.53)
1
FFS
§
Significant 31% reduction
in the risk of progression or
death from prostate cancer vs D+ADT (HR: 0.69; 95%
CI: 0.50, 0.95; p=0.023)
1
§
Significant 44% reduction
in the risk of biochemical failure,
progression or death from prostate cancer vs D+ADT (HR:
0.56;
95% CI: 0.42, 0.75; p<0.001)
1
*Data are presented for the subgroup of patients with metastatic (M1) disease at randomisation in the STAMPEDE trial
Note, median OS, PFS and FFS have not been reported for the STAMPEDE trial
Sydes M et al. Ann Oncol 2018;29(5):1235-1248
Direct comparisons in the STAMPEDE trial demonstrated
that PFS and FFS were significantly improved with
AA+P+ADT vs D+ADT in patients with mHSPC*
OS
PFS
§
No significant difference
in the risk of death vs D+ADT
(HR: 1.13; 95% CI: 0.77, 1.66; p=0.53)
1
FFS
§
Significant 31% reduction
in the risk of progression or
death from prostate cancer vs D+ADT (HR: 0.69; 95%
CI: 0.50, 0.95; p=0.023)
1
§
Significant 44% reduction
in the risk of biochemical failure,
progression or death from prostate cancer vs D+ADT (HR:
0.56;
95% CI: 0.42, 0.75; p<0.001)
1
AA, abiraterone acetate; ADT, androgen-deprivation therapy; CI, confidence interval; D, docetaxel; FFS, failure-free survival;
*Data are presented for the subgroup of patients with metastatic (M1) disease at randomisation in the STAMPEDE trial
Note, median OS, PFS and FFS have not been eported for the STAMPEDE trial
Sydes M et al. Ann Oncol 2018;29(5):1235-1248
Favours
SOC+AAP
Failure-free
survival
Progression-free
survival
Symptomatic skeletal
events
Cause-specific
survival
Overall survival
0.5
1.0
2.0
Hazard ratio
Metastatic
progression-free
survival
Favours
SOC+DocP
Figur 4.
Depiction of disease state over time.
Original article